Indefinite Delivery Contract 75D30126D20723

The Centers for Disease Control and Prevention awarded a multiple-award Indefinite Delivery/Indefinite Quantity contract to AstraZeneca Pharmaceuticals LP under solicitation 75D30125R73357 for the procurement of pediatric influenza vaccines targeting children ages 0-18. The contract, valued at $32.01 million with a ceiling date of February 28, 2027, supports the Vaccine for Children program established under the Omnibus Budget Reconciliation Act of 1993, which provides vaccines at no cost to Medicaid-eligible children, uninsured children, American Indian/Alaska Native children, and children with insurance that does not cover vaccine costs. AstraZeneca, a foreign-owned pharmaceutical manufacturer headquartered in Wilmington, Delaware, was selected based on technical compliance, pricing, and past performance evaluations. The contract operates under a firm-fixed price delivery order structure with a combined ceiling of either six million doses or $710 million across all awarded contracts, whichever is reached first, with individual contract minimums of 100 doses and maximums of 30 million doses per contract.

Vaccines procured under this contract must be manufactured in compliance with FDA requirements and maintain a shelf life extending no earlier than June 30, 2027, with delivery to CDC centralized distribution locations in Olive Branch, Mississippi, and Clermont, Kentucky, with anticipated delivery commencing Fall 2026. The original solicitation, posted August 14, 2025, with a deadline of August 28, 2025, included small business subcontracting requirements totaling 12.17 percent small business participation across multiple small business categories, including disadvantaged, HUBZone, women-owned, and service-disabled veteran-owned small business enterprises. No set-aside designation was applied to this procurement, reflecting AstraZeneca's classification as a large, established pharmaceutical manufacturer capable of meeting complex federal vaccine procurement requirements. The contract period extends from the award date of December 31, 2025, through February 28, 2027.